Price T Rowe Associates Inc. MD Buys 950,557 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Price T Rowe Associates Inc. MD lifted its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 596.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,109,978 shares of the company's stock after purchasing an additional 950,557 shares during the period. Price T Rowe Associates Inc. MD owned about 2.12% of Janux Therapeutics worth $59,429,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Russell Investments Group Ltd. increased its holdings in Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock worth $54,000 after acquiring an additional 442 shares during the period. Avanza Fonder AB purchased a new stake in Janux Therapeutics in the fourth quarter worth about $139,000. Meeder Asset Management Inc. purchased a new position in shares of Janux Therapeutics during the fourth quarter valued at approximately $159,000. Tower Research Capital LLC TRC grew its stake in shares of Janux Therapeutics by 878.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company's stock worth $205,000 after buying an additional 3,436 shares during the last quarter. Finally, Chicago Capital LLC purchased a new position in Janux Therapeutics in the 4th quarter worth about $230,000. Hedge funds and other institutional investors own 75.39% of the company's stock.

Janux Therapeutics Trading Up 2.6 %

JANX traded up $0.83 during trading hours on Friday, hitting $32.88. 825,257 shares of the company's stock were exchanged, compared to its average volume of 849,212. The firm has a 50 day moving average of $29.80 and a 200 day moving average of $42.70. The firm has a market cap of $1.95 billion, a P/E ratio of -28.10 and a beta of 3.27. Janux Therapeutics, Inc. has a 12-month low of $22.52 and a 12-month high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, research analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on JANX. Wedbush reiterated an "outperform" rating and set a $76.00 target price (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. William Blair reiterated an "outperform" rating on shares of Janux Therapeutics in a research report on Friday, January 10th. Scotiabank lowered their price objective on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research note on Friday, February 28th. Finally, HC Wainwright reiterated a "buy" rating and set a $70.00 price target on shares of Janux Therapeutics in a research note on Monday, March 3rd. One analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Janux Therapeutics currently has an average rating of "Buy" and an average target price of $95.25.

Insider Activity

In other Janux Therapeutics news, Director Ra Capital Management, L.P. acquired 110,206 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was acquired at an average price of $31.02 per share, with a total value of $3,418,590.12. Following the transaction, the director now directly owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. This represents a 1.10 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $32.15, for a total value of $107,188.10. Following the sale, the insider now directly owns 82,139 shares in the company, valued at $2,640,768.85. The trade was a 3.90 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,002 shares of company stock worth $348,203 over the last three months. 29.40% of the stock is currently owned by corporate insiders.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.